147 results on '"Domingo-Domènech, Eva"'
Search Results
2. Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma
3. Unraveling the genetics of transformed splenic marginal zone lymphoma
4. Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2
5. Epigenetic loss of m1A RNA demethylase ALKBH3 in Hodgkin lymphoma targets collagen, conferring poor clinical outcome
6. A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma
7. Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain
8. Neutropenia during frontline treatment of advanced Hodgkin lymphoma: Incidence, risk factors, and management
9. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
10. Blood neurofilaments as biomarkers of chemotherapy-induced peripheral neurotoxicity
11. Comparison of different automatic methods for the delineation of the total metabolic tumor volume in I–II stage Hodgkin Lymphoma
12. Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma
13. P1130: FRONTLINE BRENTUXIMAB VEDOTIN AND CHP (A+CHP) IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA WITH LESS THAN 10% CD30 EXPRESSION: INITIAL SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY SGN35-032
14. P1142: AFM13 IN PATIENTS WITH R/R PERIPHERAL T CELL LYMPHOMA (PTCL): A POST-HOC SUBGROUP ANALYSIS FROM THE REDIRECT STUDY
15. Peripheral T-cell lymphoma with a T follicular-helper phenotype: A different entity? Results of the Spanish Real-T study
16. The long term follow-up of early stage follicular lymphoma treated with radiotherapy, chemotherapy or combined modality treatment
17. CCR5 Δ32 homozygous cord blood allogeneic transplantation in a patient with HIV: a case report
18. T098: Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial.
19. T021: Radiation-Free Therapy as the INitial treatment of Good-prognosis early non-bulky Hodgkin lymphoma, defined by a low Metabolic Tumor Volume and a negative PET-2 - RAFTING Trial.
20. Primary cutaneous marginal zone B-cell lymphoma: Response to treatment and disease-free survival in a series of 137 patients
21. TCL-394 Valemetostat for Patients With R/R Peripheral T-Cell Lymphomas (PTCLs): A Phase 2 VALENTINE-PTCL01 Trial
22. Valemetostat for Patients With R/R Peripheral T-Cell Lymphomas (PTCLs): A Phase 2 VALENTINE-PTCL01 Trial
23. Biological Agents in the Management of Felty's Syndrome: A Systematic Review
24. NT-proBNP: A cardiac biomarker to assess prognosis in non-Hodgkin lymphoma
25. The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma
26. Systemic rituximab for the treatment of the indolent forms of primary cutaneous B-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry
27. Comprehensive Geriatric Assessment in Diffuse Large B-Cell Lymphomas Patients Older Than 70 Years Old: Prospective Single-Center Experience
28. Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early-Stage Classical Hodgkin Lymphoma (SGN35-027 Part C)
29. PET4 Response As an Independent Predictor of Long-Term Outcomes in ECHELON2 (A+CHP Vs. CHOP) in CD30+PTCL
30. Impact of Front-Line Treatment Interim PET/CT in Peripheral T-Cell Lymphoma Patients' Survival: Experience of a Single Center
31. Neurofilaments As Serum Biomarkers of Brentuximabvedotin-Induced Peripheral Neurotoxicity in CD30 + Lymphoma Patients: A Prospective Single-Center Study
32. Efficacy and Safety of Valemetostat Monotherapy in Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas: Primary Results of the Phase 2 VALENTINE-PTCL01 Study
33. Beyond remission: secondary primary malignancies in patients with lymphoma after autologous haematopoietic stem-cell transplantation
34. Epigenetic loss of m1A RNA demethylase ALKBH3 in Hodgkin lymphoma targets collagen conferring poor clinical outcome
35. Clinical and pathological characteristics of peripheral T-cell lymphomas in a Spanish population: a retrospective study
36. The direct and indirect effects of COVID‐19 pandemic in a real‐life hematological setting
37. Influence of familial cancer history on lymphoid neoplasms risk validated in the large European case-control study epilymph
38. Liquid biopsy for disease monitoring after anti‐CD19 chimeric antigen receptor T cell in diffuse large B‐cell lymphoma
39. Treatment of Hodgkin Lymphoma Relapsed after Autologous Stem Cell Transplantation
40. Organizing pneumonia in a patient with hodgkin’s lymphoma and large B cell lymphoma: a rare association
41. Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study
42. Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma
43. TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma
44. Poster: TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma
45. Oral Abstract: TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma
46. Brentuximab vedotin for lymphoma in paediatric patients
47. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease
48. Analysis of the Different Surveillance Strategies for Patients with Hodgkin Lymphoma in Clinical Remission after First-Line Treatment. a Study of the Geltamo Group (Spanish lymphoma and autologous transplant group)
49. Impact of a Tailored Nutritional and Physical Exercise Programme on Efficacy and Functional Outcomes in Older Patients with Hematological Malignancies Classified By Frailty Profile
50. Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.